retatrutide phase 2 results obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Thailand — How to

Credit & Debit Cards Accepted Pay with Visa, Mastercard, Amex, or Discover at checkout

Tirzepatide is not indicated for patients with type 1 diabetes

When it comes to taking GLP-1 medications for weight loss, side effects matterespecially when youre committing to a long-term plan

The side effect profile observed in clinical trials shares similarities with other incretin-based therapies, which is not surprising given the overlapping mechanisms of action

Development of composite PLGA microspheres containing exenatide-encapsulated lecithin nanoparticles for sustained drug release

Experts have previously called for further research in the area